leadf
logo-loader
viewMindset Pharma Inc
(
CSE:MSETOTCQB:MSSTFFRA:9DF
)

Mindset Pharma further validates lead candidate MSP-1014 as a next generation psilocybin analog through drug discrimination assay

Mindset Chief Scientific Officer Joseph Araujo said the results "further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate"

Mindset Pharma Inc - Mindset Pharma further validates lead candidate MSP-1014 as a next generation psilocybin analog through drug discrimination assay
The results suggest that MSP-1014 induces 'a similar perceptual state to psilocybin, further confirming the viability of MSP-1014'

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF), a drug discovery company focused on creating next-generation psychedelic medicines to treat neurological and psychiatric disorders, announced that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay. 

The Toronto-based company said the results suggest that MSP-1014 induces a “similar perceptual state to psilocybin, further confirming the viability of MSP-1014 as a therapeutic analog of first-generation psilocybin” as the company advances MSP-1014 into the clinic. 

“In the drug discrimination assay, MSP-1014 demonstrated a dose-dependent and full generalization to a psilocybin discriminative cue in rats,” Mindset Pharma Chief Scientific Officer Joseph Araujo said in a statement. 

READ: Mindset Pharma selects Treatment-Resistant Depression and End of Life Cancer Angst as initial target indications for MSP-1014

“Furthermore, we identified an effective dosage of 0.6 mg/kg for subcutaneous administration of MSP-1014 with no detrimental effect on the response rate up to doses of 2 mg/kg. MSP-1014 also showed a dose-dependent generalization to a psilocybin cue following the oral route of administration. These results further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate,” he added.

MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second-generation psilocybin-like therapy with decreased potential for side effects. The company has selected Treatment-Resistant Depression (TRD) and End of Life Cancer Angst as initial target indications for its lead clinical candidate MSP-1014.

Mindset Pharma said it continues to perform studies across various preclinical models with MSP-1014 and its library of next-generation psychedelic compounds.

“Our goal is to show the differentiation of our novel drug candidates and build a catalog of translational data as we prepare for human clinical trials,” said Mindset Pharma CEO James Lanthier.

Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: Mindset Pharma Inc

Follow
CSE:MSET

Price: 0.84 CAD

Market Cap: $60.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mindset Pharma say latest results further validate lead candidate's...

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay. Araujo and Lanthier...

6 days, 11 hours ago

2 min read